Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A1 receptor agonists in rats: Prediction of tissue-dependent efficacy in vivo

Journal of Pharmacology and Experimental Therapeutics

Volumn 290, Issue 2, 1999, Pages 702-709

  Van Der Graaf, Piet H ^a   Van Schaick, E A ^a   Visser, S A G ^a   De Greef, H J M M ^a   Ijzerman, A P ^a   Danhof, M ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A1 RECEPTOR AGONIST;

ANIMAL EXPERIMENT; ARTICLE; BRADYCARDIA; CARDIOVASCULAR EFFECT; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HEART RATE; LIPOLYSIS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY;

ADENOSINE; ANIMALS; AORTA, ABDOMINAL; FATTY ACIDS, NONESTERIFIED; HEART RATE; INFUSIONS, INTRAVENOUS; LIPOLYSIS; MALE; MODELS, BIOLOGICAL; ORGAN SPECIFICITY; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTORS, PURINERGIC P1;

EID: 0032789519     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Barlow RB, Scott NC and Stephenson RP (1967) The affinity and efficacy of onium salts on the frog rectus abdominis. Br J Pharmacol Chemother 31:188-196.
2. Beal SL and Sheiner LB (1992) NONMEM User's Guides. NONMEM Project Group, University of California at San Francisco, San Francisco.
3. Black JW (1996) A personal view of pharmacology. Annu Rev Pharmacol Taxicol 36:1-33.
4. Black JW and Leff P (1983) Operational models of pharmacological agonism. Proc R Soc Lond B 220:141-162.
5. 1 adenosine receptors in atrial and ventricular myocardium from diseased human hearts. Circ Res 66:1201-1211.
6. 1-receptor agonists in streptozotocin-treated rats. J Cardiovasc Pharmacol 29:417-426.
7. Dayneka NL, Garg V and Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21:457-478.
8. Donnelly R and Qu X (1998) Mechanisms of insulin resistance and new pharmacological approaches to metabolism and diabetic complications. Clin Exp Pharmacol Physiol 26:79-87.
9. du Souich P, Verges J and Erill S (1993) Plasma protein binding and pharmacological response. Clin Pharmacokinet 24:435-440.
10. Foley JE, Anderson RC, Bell PA, Burkey BF, Deems RO, de Souza C and Dunning BE (1997) Pharmacological strategies for reduction of lipid availability. Ann N Y Acad Sci 827:231-245.
11. A, Linden J, Schwabe U and Stiles GL (1998) Adenosine Receptors, in The IUPHAR Compendium of Receptor Characterization and Classification pp 48-57, IUPHAR Media Ltd., London.
12. Green A, Swenson S, Johnson JL and Partin M (1989) Characterization of human adipocyte adenosine receptors. Biochem Biophys Res Commun 163:137-142.
13. Ijzerman AP, Van der Wenden EM, Roelen HCPF, Mathôt RAA and Von Frijtag Drabbe Künzel JK (1996) Partial agonists for adenosine receptors, in Perspectives in Receptor Research (Giardina D, Piergentili A and Pigini M eds) pp 181-192, Elsevier Science, Amsterdam.
14. 1 receptor agonist, in spontaneously hypertensive rat complicated with hyperglycemia. Diabetes Res Clin Pract 39:3-9.
15. Jusko WJ and Ko HC (1994) Physiological indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 56:406-419.
16. Kenakin T (1993) Drug design and discovery, in Pharmacological Analysis of Drug-Receptor Interaction, 2nd ed, pp 441-468, Raven Press, New York.
17. 2 (DP) receptors: Estimation of affinities and relative efficacies for a series of novel bicydic ligands. Br J Pharmacol 106:996-1003. With an appendix on goodness-of-fit analyses.
18. Leff P, Prentice DJ, Giles H, Martin GR and Wood J (1990) Estimation of agonist affinity and efficacy by direct, operational model-fitting. J Pharmacol Toxicol Methods 23:225-237.
19. 125I]hydroxyphenylisopropyladenosine, an adenosine R-site agonist radioligand and theoretical analysis of mixed stereoisomer radioligand binding. Mol Pharmacol 26:414-423.
20. 1 adenosine receptors. Naunyn-Schmiedeberg's Arch Pharmacol 336:204-210.
21. 1 adenosine receptors in isolated rat ventricular myocytes. Naunyn-Schmiedeberg's Arch Pharmacol 336:342-348.
22. 1 receptor in vivo. Br J Pharmacol 116:1957-1964.
23. Meester BJ, Shankley NP, Welsh NJ, Wood J, Meijler FL and Black JW (1998) Pharmacological classification of adenosine receptors in the sinoatrial and atrioventricular nodes of the guinea-pig. Br J Pharmacol 124:685-692.
24. Ralevic V and Burnstock G (1998) Receptors for purines and pyrimidines. Pharmacol Rev 50:413-492.
25. 1 receptors. J Med Chem 39:1463-1471.
26. Rowland M and Tozer TN (1995) Distribution kinetics, in Clinical Pharmacokinetics. Concepts and Applications, 3rd ed, pp 313-339, Williams & Wilkins, Baltimore.
27. Schoemaker RC and Cohen AF (1996) Estimating impossible curves using NON-MEM. Br J Clin Pharmacol 42:283-290.
28. Shankley NP, Harper E, Roberts S, Watt G and Black J (1998) From receptor bio-assay to clinical drug effect: Clinical application of receptor theory in rational drug development, in Measurement and Kinetics of In Vivo Drug Effects (Danhof M and Steimer JL eds) pp 11-13, LACDR, Leiden, The Netherlands.
29. 1-adrenoceptor contractile responses in the tail artery of spontaneously hypertensive rats. Br J Pharmacol 119:765-771.
30. Van der Graaf PH and Danhof M (1997a) Analysis of drug-receptor interactions in vivo: A new approach in pharmacokinetic-pharmacodynamic modelling. Int J Clin Pharmacol Ther 35:442-446.
31. Van der Graaf PH and Danhof M (1997b) On the reliability of affinity and efficacy estimates obtained by direct operational model fitting of agonist concentration-effect curves following irreversible receptor inactivation. J Pharmacol Toxicol Methods 38:81-85.
32. 1-adrenoceptor-mediated pressor activity. Naunyn-Schmiedeberg's Arch Pharmacol 354:389-392.
33. 1 receptors. J Pharmacol Exp Ther 283:809-816.
34. Van der Wenden EM, Von Frijtag Drabbe Kunzel JK, Mathôt RAA, Danhof M, Uzerman AP and Soudijn W (1995) Ribose-modified adenosine analogs as potential partial agonists for the adenosine receptor. J Med Chem 38:4000-4006.
35. 1 receptor agonists. J Pharmacokinet Biopharm 25:673-694.
36. 6-(p-sulphcphenyl)adenosine in rats. Br J Pharmacol 122:525-533.
37. 1 receptors in vivo. J Pharmacol Exp Ther 283:800-808.
38. Van Schaick EA, Tukker EE, Roelen HCPF, Uzerman AP and Danhof M (1998) Selectivity of action of 8-alkylamino analogs of N6-cyclopentyladenosine in vivo: Haemodynamic versus anti-lipolytic responses in rats. Br J Pharmacol 124:607-618.
39. 1-adrenoceptors in the vas deferens of spontaneously hypertensive rat. Naunyn-Schmiedeberg's Arch Pharmacol 356:383-391.
40. Wilson S, Chambers JK, Park JE, Ladurner A, Cronk DW, Chapman CG, Kallender H, Browne MJ, Murphy GJ and Young PW (1996) Agonist potency at the cloned human beta-3 adrenoceptor depends on receptor expression level and nature of assay. J Pharmacol Exp Ther 279:214-221.